Skip to content
Androgen deprivation therapy & insulin resistance
avatar
BillH99 posted:
Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? - Abstract
Division of Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

Androgen deprivation therapy (ADT) is standard of care for patients with metastatic hormone-sensitive prostate cancer (HSPC), yet through its induction of a hypogonadal state leads to metabolic perturbations, including insulin resistance (IR) and obesity. IR and obesity have been associated with an increased risk of progression to castrate-resistant prostate cancer (CRPC) and ultimately increased prostate cancer-specific mortality. On a molecular level, this association between obesity/IR and prostate cancer progression may be mediated by alterations in the insulin-like growth factor (IGF) axis, which has been shown to be up-regulated upon disease progression to CRPC. Targeting the IGF axis, either by anti-IGF therapy or via enhancement of peripheral insulin sensitivity, represents a viable therapeutic target in patients with prostate cancer. Using the development of IR and/or obesity may represent a clinically available biomarker that may predict those patients most likely to respond to such therapy, and warrants testing in future prospective clinical trials.
Written by:
Aggarwal RR, Ryan CJ, Chan JM. Are you the author?
Reference: Urol Oncol. 2011 Jun 7. Epub ahead of print.
doi: 10.1016/j.urolonc.2011.05.001
[a>PubMed Abstract
PMID: 21658978
UroToday.com Prostate Cancer Section
Was this Helpful?
1 of 2 found this helpful
Reply
 
avatar
BobKy responded:
Hi BillH99,

Thanks!

Researchers have been looking at the IGF/PCa relationship for years;hopefully, they're getting closer to understanding why this happens and how to use it in treating PCa.


Bob


Helpful Tips

Using Social Fundraising
The costs of treating and surviving prostate cancer can be staggering, and insurance doesn't cover everything. Using social fundraising ... More
Was this Helpful?
0 of 0 found this helpful

Related News

There was an error with this newsfeed

Related Drug Reviews

  • Drug Name User Reviews

Report Problems With Your Medications to the FDA

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

For more information, visit the Duke Health Prostate Cancer Center